Utilization of Formulation and Devices for Intranasal Delivery

  • Highlight general formulation and delivery learnings from model peptide/biologic compounds and how they pair with Aptar devices and proof of concept in vivo data
  • Discuss formulation and device strategies to enable delivery of mucosal vaccines
  • Emphasize using formulation, device, and in vivo studies to address problem statements in intranasal drug delivery with the following